UPDATE: Lilly shares slip following Zyprexa news
Shares of Eli Lilly and Co. fell this morning after the company announced regulators had rejected its application for a long-acting, injectible version of its best-selling drug, Zyprexa. Lilly’s stock price fell roughly 2 percent, to $50.73. The U.S. Food and Drug Administration said in a “not approvable” letter that it needs more information on […]